<DOC>
	<DOCNO>NCT00611455</DOCNO>
	<brief_summary>This phase III , double-blind , randomize , multicenter , parallel group trial duration 24 week , follow 120 week Open-label Period . primary purpose study demonstrate efficacy ofatumumab reduce clinical sign symptom adult RA patient single course ofatumumab .</brief_summary>
	<brief_title>Investigating Clinical Efficacy Ofatumumab Adult Rheumatoid Arthritis ( RA ) Patients Who Had Inadequate Response MTX Therapy</brief_title>
	<detailed_description>This study consist Double-blind , placebo control , parallel group part eligible patient enrol 24 week Double-Blind Period , randomize 1:1 ratio receive ofatumumab ( 700mg x 2 infusion ) placebo ( saline x 2 infusion ) addition background methotrexate treatment . Patients complete 24 week Double-Blind period without receive rescue DMARD treatment eligible proceed 120 week Open-Label Period receive repeat treatment course ofatumumab . In Open-label Period ofatumumab treatment course give individualized time interval clinical response achieve follow previous treatment course , follow subsequent worsen disease activity . Patients complete Open-Label Period withdrawn enter maximum 2 year Follow-up Period , Bcells return normal baseline level , whichever occur early .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Age ≥ 18 year ; Active disease time screen define : ≥ 8 swollen joint ( 66 joint assess ) ≥ 8 tender joint ( 68 joint assess ) , CReactive Protein ( CRP ) ≥ 1.0 mg/dL Erythrocyte Sedimentation Rate ( ESR ) ≥ 22 mm/hour , DAS28≥3.2 ( base ESR ) ; Inadequate response previous current methotrexate treatment ; Treatment methotrexate ( MTX ) , 7.525 mg/week , least 12 week stable dose least 4 week . Exclusion Criteria Patients history rheumatic autoimmune disease RA significant systemic involvement secondary RA ; Previous exposure biologic antirheumatic therapy , include investigational compound ; Previous exposure biologic DMARDs ; Chronic ongoing active infectious disease require systemic treatment ; Clinically significant cardiac disease ; History significant cerebrovascular disease ; Significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease , evidence demyelinate disease ; Known HIV positive ; Serologic evidence Hepatitis B infection ; Positive test Hepatitis C ; Positive plasma / white cell JC Virus PCR ; Serum IgG &lt; low limit normal ; Breast feed woman woman positive pregnancy test screening ; Current participation interventional clinical study ; Patients know suspected able comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>